Flavio Mantelli
Graduated in Medicine and Surgery summa cum laude, Flavio completed his specialization program in ophthalmology and a Ph.D. at the Campus Bio-Medico University of Rome. He also completed a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute - Harvard Medical School in Boston.
Prior to joining Dompé, Flavio researched the application of neurotrophins in ophthalmic and neurodegenerative diseases and was an adjunct associate professor of biology at Temple University in Philadelphia. His professional experience includes positions at the IRCCS G.B. Bietti Hospital in Rome as a clinical scientist and as a consultant ophthalmologist at the Campus Biomedico University of Rome and the Cornea and Ocular Surface Unit of the Vita-Salute San Raffaele University of Milan.
Flavio joined Dompé in 2014, and has been instrumental in developing Oxervate into a revolutionary product for a rare and potentially blinding orphan corneal disease, neurotrophic keratitis. In 2019, he was appointed Chief Medical Officer and Head of R&D for the Ophthalmology and Neurotrophin platforms, leading all research and clinical development programs in ophthalmology. Since 2025, he serves as Chief Strategy & Innovation Officer (CSIO), acting as the key link between the company and external partners, with the goal of promoting Dompé’s research initiatives and assessing new opportunities aligned with industry innovations
He is the author of numerous scientific publications in international journals.